Oramed submits request for new U.S. oral insulin trial; Analysts expect the inhalation market to reach $47M by 2017;

> Oramed ($ORMP) submitted a pre-IND meeting request to the FDA for a U.S. trial of its oral insulin capsule, ORMD-0901. Release

> Industry analysts concluded that inhalation drug delivery systems are gathering momentum with the development of faster acting and more effective products, with the global market expected to reach $47 billion by 2017. Release

> Catalent bought Chinese softgel firm Zhejiang Jiang Yuan Tang Biotechnology, building upon its existing softgel network in Asia Pacific, including facilities in Japan and Australia. More

> Bespak Europe won government funding to the tune of up to £1 million ($1.52 million) from the U.K.'s Department of Health to develop a new bolus drug delivery device entering Phase II. Article

> Oxford Pharmascience extended its collaboration with University College London to further develop its drug-delivery compounds, giving Oxford the option on over 53 compounds to commercialize with the university. Article

Suggested Articles

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.

Astex's oral reformulation of a common chemo combo looks to replace lengthy infusions with a once-daily tablet that patients can take at home.